Android app Apple app link

Editas Medicine, Inc. (EDIT) Analyst Forecast

NASDAQ Currency in USD Disclaimer
Add to Alerts ADD TO LIST

$0.00

$0 (0%)
Last update: 07:00 PM EST
Day's range
$1.98
Day's range
$2.47

Recent Analyst Forecasts and Stock Ratings

Date Brokerage Firm Analyst Name Price Target Price when Posted Upside/Downside
on Report Date		 Details
09/23/2026 Guggenheim Debjit Chattopadhyay $5.00 $2.92   71.23%
11/05/2024 Barclays Gena Wang $5.00 $3.12   60.26%
10/23/2024 Wells Fargo Yanan Zhu $9.00 $3.29   173.56%
10/22/2024 Robert W. Baird Joel Beatty $10.00 $3.29   203.95%
08/08/2024 Truist Financial Joon Lee $12.00 $4.24   183.02%
08/08/2024 Bank of America Securities Greg Harrison $15.00 $4.21   256.72%
05/30/2024 Evercore ISI Liisa Bayko $7.00 $5.10   37.25%
05/08/2024 Morgan Stanley Matthew Harrison $7.00 $5.04   39.03%
09/28/2023 Stifel Nicolaus Dae Gon Ha $17.00 $6.92   145.66%
11/18/2022 Truist Financial Joon Lee $35.00 $11.01   217.89%
01/05/2022 Morgan Stanley Matthew Harrison $24.00 $24.41   -1.68%
11/07/2021 Robert W. Baird Joel Beatty $44.00 $40.57   8.45%
09/28/2021 Truist Financial Joon Lee $80.00 $42.50   88.24%

Editas Medicine Inc FAQ's

Editas Medicine Inc has been rated by research analysts at Wells Fargo, Guggenheim, Chardan Capital, Robert W. Baird, Barclays, Truist Financial in the past 90 days.

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.